Pharmaxis Ltd (AU:SNT) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Syntara Limited has announced promising interim results from its Phase 2 trial of SNT-5505 for myelofibrosis, showing significant symptom improvement and spleen volume reduction in patients. The trial, which combines SNT-5505 with ruxolitinib, highlights the potential for long-term benefits and an excellent safety profile, differentiating it from existing treatments. Investors may find the positive data and potential for future partnerships with global entities an intriguing development.
For further insights into AU:SNT stock, check out TipRanks’ Stock Analysis page.
